As the American population ages, the prevalence of glaucoma rises, thus consuming greater medical and financial resources. For the first time, MCOs are attempting to understand ophthalmologic diseases, their interest driven by the market appearance of several new pharmaceutical products to treat glaucoma. The efficacy of these products has created demand and, in turn, a need for appropriate criteria for their utilization. This digest of existing literature and best practices gives physicians and pharmacists on pharmacy and therapeutics committees up-to-date information about the most efficacious and cost-effective medical treatments available in a centralized format virtually unavailable elsewhere.
Introduction: Glaucoma Arrives on Managed Care’s Doorstep
Prevalence, Utilization, and Economic Implications
Clinical Guidelines for the Treatment of Glaucoma
Glaucoma Medications: A Drug Therapy Review
Considerations in the Pharmacoeconomics of Glaucoma
Current Formulary Status of Glaucoma Agents
Constructing Disease Management Programs for Glaucoma